Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia Resource Center

Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
From Oncology
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024

By Emry Lloyd

By Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
Conference Coverage
Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings
11/29/2023

Edited by Grace Taylor

Edited by Grace Taylor
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and...
11/29/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023

Emry Lloyd

Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways
News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023

Emry Lloyd

Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways
Conference Coverage
Use of Pharmacogenomic Testing to Predict Bruton’s Tyrosine Kinase Inhibitor Treatment Intolerance
08/09/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.
Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.
Researchers conducted a study to...
08/09/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Expert Insights

Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Adam Kittai, MD
Videos
A Real-World Analysis of Factors Leading to Racial Disparities in the Overall Survival of Patients with CLL
06/22/2023

Featuring Adam Kittai, MD

Featuring Adam Kittai, MD
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State...
06/22/2023
Journal of Clinical Pathways
Winston Wong
Editor Insights
A Look Back at Clinical Pathways in 2022
02/21/2023
Winston Wong, PharmD, Editor-in-Chief
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal...
02/21/2023
Journal of Clinical Pathways
Justin Taylor, MD
Videos
Recent Advances in Chronic Lymphocytic Leukemia Treatment
12/06/2022
Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.
Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.
Justin Taylor, MD, answers a...
12/06/2022
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Progression-Free Survival Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
08/19/2022
Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.
Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.
Kerry Rogers, MD, discusses a...
08/19/2022
Journal of Clinical Pathways
Adam Kittai, MD
Videos
Examining Racial and Socioeconomic Disparities Among Patients With Chronic Lymphocytic Leukemia
06/14/2022
Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.
Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.
Adam Kittai, MD, discusses his...
06/14/2022
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways

Newsfeed

News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024

By Emry Lloyd

By Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023

Emry Lloyd

Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways
News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023

Emry Lloyd

Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways
News
Study Analyzes Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
05/11/2023

Grace Taylor

Grace Taylor
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS,...
05/11/2023
Journal of Clinical Pathways
News
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
04/24/2023

Gina Tomaine

Gina Tomaine
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food...
04/24/2023
Journal of Clinical Pathways
News
The Ongoing Impact of COVID-19 on Caregivers of Patients With Chronic Lymphocytic Leukemia
03/15/2023

Grace Taylor

Grace Taylor
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the...
03/15/2023
Journal of Clinical Pathways
News
Elevated Risk of Atrial Fibrillation or Stroke in Patients With CLL Receiving Ibrutinib Treatment Has Minimal Impact on TTNT and TTD
02/23/2023

Grace Taylor

Grace Taylor
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the...
02/23/2023
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL
04/18/2022
True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.
True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.
True or False: Patients with CLL...
04/18/2022
Journal of Clinical Pathways
Quiz
Quiz: The Impact of Atrial Fibrillation on CLL
03/24/2022
True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.
True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.
True or False: Patients with CLL...
03/24/2022
Journal of Clinical Pathways
Quiz
Quiz: Risk of Infusion Reactions in Patients With CLL Receiving Obinutuzumab
02/22/2022
True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.
True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.
True or False: Using...
02/22/2022
Journal of Clinical Pathways
Quiz
Quiz: Ibrutinib Safety for Relapsed/Refractory CLL
01/13/2022
True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.
True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.
True or False: Single-agent...
01/13/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Venetoclax Plus Obinutuzumab for CLL
11/22/2021
True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.
True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.
True or False: Fixed duration...
11/22/2021
Journal of Clinical Pathways
Quiz
Quiz: Treatment Discontinuation Among Patients With CLL
10/19/2021
True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.
True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.
True or False: The most common...
10/19/2021
Journal of Clinical Pathways
Quiz
Quiz: Cardiovascular Risks for Patients With CLL Receiving Ibrutinib
10/08/2021
True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.
True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.
True or False: Ibrutinib is...
10/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Bendamustine Costs for Patients With CLL and NHL
09/10/2021
True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.
True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.
True or False: Small-volume,...
09/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Rituximab Cost for CLL and NHL
07/23/2021
True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
True or False: Intravenous...
07/23/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement